243 related articles for article (PubMed ID: 25197268)
1. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer.
Cecchi F; Rabe DC; Bottaro DP
Curr Signal Transduct Ther; 2011; 6(2):146-151. PubMed ID: 25197268
[TBL] [Abstract][Full Text] [Related]
2. Targeting the HGF/Met signalling pathway in cancer.
Cecchi F; Rabe DC; Bottaro DP
Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
[TBL] [Abstract][Full Text] [Related]
3. Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F; Rabe DC; Bottaro DP
Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
[TBL] [Abstract][Full Text] [Related]
4. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
6. Targeting the c-Met signaling pathway in cancer.
Peruzzi B; Bottaro DP
Clin Cancer Res; 2006 Jun; 12(12):3657-60. PubMed ID: 16778093
[TBL] [Abstract][Full Text] [Related]
7. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
9. Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.
Della Corte CM; Fasano M; Papaccio F; Ciardiello F; Morgillo F
Biomedicines; 2014 Nov; 2(4):345-358. PubMed ID: 28548075
[TBL] [Abstract][Full Text] [Related]
10. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
11. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Miranda O; Farooqui M; Siegfried JM
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
[TBL] [Abstract][Full Text] [Related]
12. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract][Full Text] [Related]
13. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H; Okamoto I
Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
[TBL] [Abstract][Full Text] [Related]
14. Promise and challenges on the horizon of MET-targeted cancer therapeutics.
Zhang YW
World J Biol Chem; 2015 May; 6(2):16-27. PubMed ID: 26009700
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.
Rothenberger NJ; Stabile LP
Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28441771
[TBL] [Abstract][Full Text] [Related]
16. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
Sylvester PW
Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
18. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
Zhang Y; Jain RK; Zhu M
Biomedicines; 2015 Mar; 3(1):149-181. PubMed ID: 28536405
[TBL] [Abstract][Full Text] [Related]
19. HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.
Gaudino G; Yang H; Carbone M
Biomedicines; 2014 Nov; 2(4):327-344. PubMed ID: 28548074
[TBL] [Abstract][Full Text] [Related]
20. Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.
Huang X; Li E; Shen H; Wang X; Tang T; Zhang X; Xu J; Tang Z; Guo C; Bai X; Liang T
Front Cell Dev Biol; 2020; 8():152. PubMed ID: 32435640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
